The ASPIRING trial aims to determine if single antiplatelet (blood-thinning) medication after a bleed (haemorrhage) in the brain is of net benefit in preventing all future serious vascular events (caused by blood clots in blood vessels, or bleeding from them).
People with a stroke due to brain haemorrhage commonly have, or are at risk of, blood vessel diseases that may cause blood to clot in the vessels and block blood supply to the brain or heart, causing an ischaemic stroke or heart attack. At present, it is uncertain if the potential benefits of single antiplatelet therapy after brain haemorrhage in preventing ischaemic stroke and heart attack offset any small risks of further bleeding.
Survivors of brain haemorrhage who are interested in participating will be asked to discuss their participation with their doctor.
If participants provide informed consent, they will be randomly allocated to either “take single antiplatelet therapy” (of either aspirin or clopidogrel) or “avoid antiplatelet therapy”.
Trial participation is for 4 years, with telephone assessments by the trial coordinating centre in Perth WA at 1, 3, and 6 months after randomisation and then 6 monthly until month 48.
If you are interested, please email firstname.lastname@example.org